

INFORMATION DISCLOSURE CITATION

(See several sheets if necessary)

Sheet 1 of 3

ATTY. DOCKET NO.
CT2775NP
APPLICATION NO.
10/799,784
APPLICANT
HARTZ ET AL.
FILING DATE
MARCH 12, 2004

Group



U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						
	AL						

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	OFFICE	CLASS	SUBCLASS	TRANSLATION YES	NO
BWYK	AM	WO 95/10506	4/20/95	PCT			<input type="checkbox"/>	<input type="checkbox"/>
	AN	WO 99/51608	10/14/99	PCT			<input type="checkbox"/>	<input type="checkbox"/>
	AO	WO 95/33750	12/14/95	PCT			<input type="checkbox"/>	<input type="checkbox"/>
	AP	WO 00/59888	10/12/00	PCT			<input type="checkbox"/>	<input type="checkbox"/>
BWYK	AQ	WO 01/68614A2	9/20/01	PCT			<input type="checkbox"/>	<input type="checkbox"/>

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent pages, Etc.)

BWYK	AR	DUNN, A.J., et al., "Physiological and behavioral responses to corticotropin-releasing factor administration: is CRF a mediator of anxiety or stress responses?" BRAIN RESEARCH REVIEWS, 15, 1990, pp. 71-100
	AS	GULYAS, J., et al., "Potent, structurally constrained agonists and competitive antagonists of corticotropin-releasing factor," PROC. NATL. ACAD. SCI. USA, Vol. 92, Nov. 1995, pp.10575-10579
BWYK	AT	McCARTHY, et al., "Recent Advances with the CRF1 Receptor: Design of Small Molecule Inhibitors, Receptor Subtypes and Clinical Indications," CURRENT PHARMACEUTICAL DESIGN, 1999, 5, pp. 289-315

EXAMINER

DATE CONSIDERED

*EXAMINER: Initial of reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.

INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

ATTY. DOCKET NO.
CT2775NP
APPLICATION NO.
10/799,784
APPLICANT
HARTZ ET AL.
FILING DATE
MARCH 12, 2004

Group



OTHER DOCUMENTS (Including Author, Title, Date, Pertinent pages, Etc.)

AA	HOLSBOER, F., "The rationale for corticotropin-releasing hormone receptor (CRH-R) antagonists to treat depression and anxiety," JOURNAL OF PSYCHIATRIC RESEARCH, 33, 1999, pp. 181-214
AB	BANKI, C.M., et al., "CSF corticotropin-releasing hormone and somatostatin in major depression: response to antidepressant treatment and relapse," EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2, 1992, pp. 107-113
AC	WEBSTER, E.L., et al., "Corticotropin-Releasing Hormone and Inflammation," ANNALS NEW YORK ACADEMY OF SCIENCES, 840, 1998, pp. 21-32
AD	GILLIGAN, P.J., et al., "Corticotropin Releasing Factor (CRF) Receptor Modulators: Progress and Opportunities for New Therapeutic Agents," JOURNAL OF MEDICINAL CHEMISTRY, Vol. 43, No. 9, May 4, 2000, pp. 1641-1660
AE	MCCARTHY, J.R., et al., "Chapter 2. Recent Progress in Corticotropin-Releasing Factor Receptor Agents," ANNUAL REPORTS IN MEDICINAL CHEMISTRY, Vol. 34, 1999, pp. 11-20
AF	
AG	
AH	
AI	
AJ	
AK	
AL	
AM	
AN	

EXAMINER

DATE CONSIDERED

9/1/04

*EXAMINER: Initial of reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.


INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

Sheet 3 of 3

ATTY. DOCKET NO.
CT2775NP
APPLICATION NO.
10/799,784
APPLICANT
HARTZ ET AL.
FILING DATE
MARCH 12, 2004

Group



FOREIGN PATENT DOCUMENTS

	DOCUMENT NUMBER	DATE	OFFICE	CLASS	SUBCLAS S	TRANSLATION YES	NO
	AA WO 97/45421	12/4/97	PCT			<input type="checkbox"/>	<input type="checkbox"/>
	AB WO 00/53604	9/14/00	PCT (English equiv U.S. 6,600,038 provided)			<input type="checkbox"/>	<input type="checkbox"/>
	AC WO 02/06242A2	1/24/02	PCT			<input type="checkbox"/>	<input type="checkbox"/>
	AD WO 98/03510	1/29/98	PCT			<input type="checkbox"/>	<input type="checkbox"/>
	AE WO 01/53263A1	7/26/01	PCT			<input type="checkbox"/>	<input type="checkbox"/>
	AF WO 01/62718	8/30/01	PCT			<input type="checkbox"/>	<input type="checkbox"/>
	AG					<input type="checkbox"/>	<input type="checkbox"/>
	AH					<input type="checkbox"/>	<input type="checkbox"/>
	AI					<input type="checkbox"/>	<input type="checkbox"/>
	AJ					<input type="checkbox"/>	<input type="checkbox"/>
	AK					<input type="checkbox"/>	<input type="checkbox"/>
	AL					<input type="checkbox"/>	<input type="checkbox"/>
	AM					<input type="checkbox"/>	<input type="checkbox"/>
	AN					<input type="checkbox"/>	<input type="checkbox"/>
	AO					<input type="checkbox"/>	<input type="checkbox"/>
	AP					<input type="checkbox"/>	<input type="checkbox"/>
	AQ					<input type="checkbox"/>	<input type="checkbox"/>
	AR					<input type="checkbox"/>	<input type="checkbox"/>
	AS					<input type="checkbox"/>	<input type="checkbox"/>
	AT					<input type="checkbox"/>	<input type="checkbox"/>
	AU					<input type="checkbox"/>	<input type="checkbox"/>
	AV					<input type="checkbox"/>	<input type="checkbox"/>
	AW					<input type="checkbox"/>	<input type="checkbox"/>
	AX					<input type="checkbox"/>	<input type="checkbox"/>
	AY					<input type="checkbox"/>	<input type="checkbox"/>
	AZ					<input type="checkbox"/>	<input type="checkbox"/>

EXAMINER

DATE CONSIDERED

9/11/04

*EXAMINER: Initial of reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.

SFW
CASE CT2775NP

CERTIFICATE OF MAILING

I hereby certify that this paper (along with any paper referred to as being attached or enclosed) is being deposited with the United States Postal Service on the date shown below with sufficient postage as first class mail in an envelope addressed to the: Assistant Commissioner for Patents, Washington, D.C. 20231.

Janet Sudo
Type or print name

Janet Sudo
Signature

June 9, 2004
Date

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF

HARTZ ET AL.

APPLICATION NO: 10/799,784

FILED: MARCH 12, 2004

FOR: PYRIMIDINE DERIVATIVES FOR THE TREATMENT OF DEPRESSION

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Sir:

This paper is being filed within three months of the filing date of the application. Therefore, no fees are required. If a fee is deemed to be required, the Commissioner is hereby authorized to charge such fee to Deposit Account No. 19-3880.

In accordance with 37 C.F.R. §1.56, applicants wish to call the Examiner's attention to the references cited on the attached form(s) PTO-1449. Copies of these references are enclosed herewith.

The Examiner is requested to consider the foregoing information in relation to this application and indicate that each reference was considered by returning a copy of the initialed PTO 1449 form(s).

Respectfully submitted,

Shah R. Makujina
Shah R. Makujina
Attorney for Applicants
Reg. No. 41,174

Bristol-Myers Squibb Company
Patent Department
P.O. Box 4000
Princeton, NJ 08543-4000
(203) 677-7268

Date: *6/4/04*